

Special Issue

Immune-Related Adverse Events in Patients with Cancer: From Bench to Bedside

Message from the Guest Editors

Although there is growing consensus regarding the management of irAEs in cancer, more work is required to elucidate their exact mechanism of action, identify predictive biomarkers, and understand the mechanisms of steroid resistance with direct therapeutic implications. Hosting perspectives from distinct subspecialties involved in preclinical as well as clinical research on irAEs, this Special Issue aims to provide a comprehensive summary of current knowledge on immunotherapy toxicity in patients with cancer. We also aim to present cutting-edge research that will shed light on various aspects of this evolving field, including but not limited to pathophysiology, taxonomy, and association with immunotherapy outcomes. A better understanding of irAEs will facilitate collaboration among different subspecialties and ultimately improve the management of immunotherapy toxicity in patients with cancer. We invite you to submit your work, including original articles, expert reviews, and commentaries on this important subject.

Guest Editors

Prof. Dr. Konstantinos Syrigos

Dr. Ioannis Vathiotis

Dr. Nikolaos K. Syrigos

Deadline for manuscript submissions

closed (31 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/164998

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)